FCA
COCP icon

FinTrust Capital Advisors’s Cocrystal Pharma COCP Stock Holding History

FinTrust Capital Advisors’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-23
Closed – – 1224
2022
Q1 		$0 Hold
23
– – ﹤0.01% 1227
2021
Q4 		$0 Buy
+23
New +$235 ﹤0.01% 1197

Other funds holding COCP

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FinTrust Capital Advisors's COCP Position: Q2 2022 in Review

FinTrust Capital Advisors sold out of Cocrystal Pharma (COCP) in Q2 2022, closing a stake of 23 shares.

FinTrust Capital Advisors first reported a position in COCP in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 33 funds tracked by Wall St. Rank hold COCP as of Q2 2022.

  • FinTrust Capital Advisors reported no remaining Cocrystal Pharma position as of Q2 2022 after selling out during the quarter.
  • FinTrust Capital Advisors sold 23 Cocrystal Pharma shares in Q2 2022.
  • FinTrust Capital Advisors first reported a position in Cocrystal Pharma in Q4 2021 and held it in 2 quarters.
  • FinTrust Capital Advisors's Cocrystal Pharma position peaked at $0 in Q1 2022.
  • 33 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q2 2022.

Based on FinTrust Capital Advisors's 13F filing for Q2 2022, filed 26 Jul 2022.